» Articles » PMID: 26472029

The PIM Inhibitor AZD1208 Synergizes with Ruxolitinib to Induce Apoptosis of Ruxolitinib Sensitive and Resistant JAK2-V617F-driven Cells and Inhibit Colony Formation of Primary MPN Cells

Overview
Journal Oncotarget
Specialty Oncology
Date 2015 Oct 17
PMID 26472029
Citations 25
Authors
Affiliations
Soon will be listed here.
Abstract

Classical myeloproliferative neoplasms (MPNs) are hematopoietic stem cell disorders that exhibit excess mature myeloid cells, bone marrow fibrosis, and risk of leukemic transformation. Aberrant JAK2 signaling plays an etiological role in MPN formation. Because neoplastic cells in patients are largely insensitive to current anti-JAK2 therapies, effective therapies remain needed. Members of the PIM family of serine/threonine kinases are induced by JAK/STAT signaling, regulate hematopoietic stem cell growth, protect hematopoietic cells from apoptosis, and exhibit hematopoietic cell transforming properties. We hypothesized that PIM kinases may offer a therapeutic target for MPNs. We treated JAK2-V617F-dependent MPN model cells as well as primary MPN patient cells with the PIM kinase inhibitors SGI-1776 and AZD1208 and the JAK2 inhibitor ruxolitinib. While MPN model cells were rather insensitive to PIM inhibitors, combination of PIM inhibitors with ruxolitinib led to a synergistic effect on MPN cell growth due to enhanced apoptosis. Importantly, PIM inhibitor mono-therapy inhibited, and AZD1208/ruxolitinib combination therapy synergistically suppressed, colony formation of primary MPN cells. Enhanced apoptosis by combination therapy was associated with activation of BAD, inhibition of downstream components of the mTOR pathway, including p70S6K and S6 protein, and activation of 4EBP1. Importantly, PIM inhibitors re-sensitized ruxolitinib-resistant MPN cells to ruxolitinib by inducing apoptosis. Finally, exogenous expression of PIM1 induced ruxolitinib resistance in MPN model cells. These data indicate that PIMs may play a role in MPNs and that combining PIM and JAK2 kinase inhibitors may offer a more efficacious therapeutic approach for MPNs over JAK2 inhibitor mono-therapy.

Citing Articles

SHP2 inhibition displays efficacy as a monotherapy and in combination with JAK2 inhibition in preclinical models of myeloproliferative neoplasms.

Pandey G, Mazzacurati L, Rowsell T, Horvat N, Amin N, Zhang G Am J Hematol. 2024; 99(6):1040-1055.

PMID: 38440831 PMC: 11096011. DOI: 10.1002/ajh.27282.


An overview of pim kinase as a target in multiple myeloma.

Liu Z, Zhang Y, Guo Y, Wang H, Fu R Cancer Med. 2023; 12(10):11746-11759.

PMID: 37162273 PMC: 10242321. DOI: 10.1002/cam4.5797.


Targeting Pim kinases in hematological cancers: molecular and clinical review.

Bellon M, Nicot C Mol Cancer. 2023; 22(1):18.

PMID: 36694243 PMC: 9875428. DOI: 10.1186/s12943-023-01721-1.


Combination of Resminostat with Ruxolitinib Exerts Antitumor Effects in the Chick Embryo Chorioallantoic Membrane Model for Cutaneous T Cell Lymphoma.

Karagianni F, Piperi C, Casar B, de la Fuente-Vivas D, Garcia-Gomez R, Lampadaki K Cancers (Basel). 2022; 14(4).

PMID: 35205818 PMC: 8870185. DOI: 10.3390/cancers14041070.


Understanding Aberrant Signaling to Elude Therapy Escape Mechanisms in Myeloproliferative Neoplasms.

Bochicchio M, Di Battista V, Poggio P, Carra G, Morotti A, Brancaccio M Cancers (Basel). 2022; 14(4).

PMID: 35205715 PMC: 8870427. DOI: 10.3390/cancers14040972.


References
1.
Xing S, Wanting T, Zhao W, Ma J, Wang S, Xu X . Transgenic expression of JAK2V617F causes myeloproliferative disorders in mice. Blood. 2008; 111(10):5109-17. PMC: 2384138. DOI: 10.1182/blood-2007-05-091579. View

2.
Tefferi A, Skoda R, Vardiman J . Myeloproliferative neoplasms: contemporary diagnosis using histology and genetics. Nat Rev Clin Oncol. 2009; 6(11):627-37. DOI: 10.1038/nrclinonc.2009.149. View

3.
Chen L, Redkar S, Bearss D, Wierda W, Gandhi V . Pim kinase inhibitor, SGI-1776, induces apoptosis in chronic lymphocytic leukemia cells. Blood. 2009; 114(19):4150-7. PMC: 2774551. DOI: 10.1182/blood-2009-03-212852. View

4.
Wang Y, Fiskus W, Chong D, Buckley K, Natarajan K, Rao R . Cotreatment with panobinostat and JAK2 inhibitor TG101209 attenuates JAK2V617F levels and signaling and exerts synergistic cytotoxic effects against human myeloproliferative neoplastic cells. Blood. 2009; 114(24):5024-33. PMC: 2788976. DOI: 10.1182/blood-2009-05-222133. View

5.
Quintas-Cardama A, Vaddi K, Liu P, Manshouri T, Li J, Scherle P . Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms. Blood. 2010; 115(15):3109-17. PMC: 3953826. DOI: 10.1182/blood-2009-04-214957. View